# Everolimus and Capecitabine in Patients With Advanced Malignancy

> **NCT01079702** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 35 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01079702
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2010-04
- **Final completion:** 2011-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2010-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01079702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01079702, "Everolimus and Capecitabine in Patients With Advanced Malignancy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01079702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*